Advertisement: Bridge Fibre mid
Advertisement: CPL mid banner
Advertisement: Cambridge Network
Advertisement: Lynch Wood Park
Advertisement: KISS
Advertisement: Bradfield Centre mid
Advertisement: Wild Knight Vodka
RealVNC mid banner careers
Barr Ellison Solicitors – commercial property
Advertisement: Mobas mid banner
TTP
Advertisement: mid banner EY
RealVNC mid-banner general
ARM Innovation Hub
15 August, 2018 - 15:24 By Kate Sweeney

Researchers revive forgotten antibiotics in a bid to save more lives

Scientists in Norwich are part of a drive to readdress forgotten antibiotics in a bid to reinvigorate potentially lifesaving drugs.

They are building a free, open-access, searchable database of many once-promising leads from the past 50 years which have been shelved for various reasons.

The team behind AntibioticDB is led by Professor Laura Piddock from the University of Birmingham and includes scientists from the John Innes Centre; they argue that previously discontinued agents are an untapped resource that have been overlooked by drug-development companies.

They say the current state of antibiotic discovery, research and development is insufficient to respond to the urgent need for treatments of drug-resistant bacterial infections.

The scientists hope this new online memory bank of forgotten antibiotics could deliver tomorrow’s lifesaving drugs.

In addition to discontinued compounds – some of them dating back to the 1960s – the database includes data on discovery, research and clinical trials and compounds awaiting approval.

“We wanted to establish the current status of the drug-discovery pipeline in antibiotic development –particularly to look at compounds that might have been dropped in the past to see if they could be resuscitated,” says one of the authors of the study, Professor Tony Maxwell of the John Innes Centre.

“The study establishes a readily usable database of antibiotics that can be accessed for free by anybody; we hope this will help both academia and commercial companies with their drug-discovery efforts.”

The research team used a range of sources to identify compounds of interest, including key opinion leaders in the pharmaceutical industry and top agencies in this research area.

Information on each compound or drug was obtained using online searches, literature archives and interviewing prominent experts. Further information such as reasons for the lack of development is also included.

The study highlights examples from the past where drugs have been dropped on safety grounds, only to be re-introduced successfully years later after new research showed them to be safe at different dosages.

While other pay-per-view resources exist for researchers, AntibioticDB is the first free database designed to appeal to small and medium-sized enterprises or academia.

In 2009 the World Health Organisation declared antimicrobial resistance one of the biggest threats to human health which, if not addressed with the introduction of new effective antibiotics, could by 2050 kill more people than cancer or road traffic accidents.

Lead author Professor Laura Piddock, of the University of Birmingham’s Institute of Microbiology and Infection, said: “It can take up to 15 years and cost up to $5 billion from the discovery of a compound to progress through pre-clinical and clinical development before a medicine can be licensed and then marketed.

“There is no doubt that the antibiotic pipeline needs revitalisation; however, the answer may be not only the development of new drugs but also re-investigating compounds previously discontinued.”

• PHOTOGRAPH SHOWS: Professor Tony Maxwell

Newsletter Subscription

Stay informed of the latest news and features